The study with the lead compound AP-325 shows meaningful pain reduction in patients with peripheral post-surgical neuropathic pain, with fewer side effects.
As Science Investor, we build bridges of various kinds, overcoming challenges and bridging differences, thus connecting different worlds and perspectives.
The OCCIDENT Team reviews the past eventful year and tunes in to Christmas. And at the same time, we are looking forward to the new opportunities that await us in the new year.
The agreement, valued at up to $415 million, combines Gilead's long-standing expertise with Tubulis' innovative technology to advance ADC treatment for solid tumors.
Phase I Trial data show safety and potential efficacy in heavily pre-treated soft tissue sarcoma patients. In 4 out of 6 patients, the disease remained stable per RECIST.